SS-31
Also known as: Elamipretide, Bendavia, MTP-131
Overview
SS-31 (Elamipretide) represents one of the clinically studied mitochondria-targeting peptides currently available. Unlike typical peptides that work through receptor pathways, research suggests SS-31 directly enters cells' powerhouses to optimise energy production at its source.
Developed by Stealth BioTherapeutics, this synthetic tetrapeptide has progressed through multiple clinical trials for mitochondrial-related conditions. Studies indicate it's currently in Phase II trials including the TAZPOWER study for Barth syndrome and has shown promising results in other mitochondrial disease research.
The peptide appears to work by stabilising cardiolipin, a critical phospholipid in mitochondrial membranes. Clinical evidence from a small 12-participant study suggests SS-31 may produce measurable improvements in exercise capacity, with the TAZPOWER trial showing a 1.60 mL/kg/min increase in peak VO2 and 36-metre improvement in 6-minute walk distance.
Who's using SS-31? Beyond clinical trial participants with rare mitochondrial diseases, it's being studied by researchers and longevity enthusiasts targeting cellular energy optimisation. The peptide's proposed mechanism — preventing excess reactive oxygen species production rather than simply scavenging them — appeals to those seeking evidence-based anti-ageing interventions.
What distinguishes SS-31 from other mitochondrial supplements is its specificity. Rather than broad-spectrum antioxidant effects, it specifically targets the electron transport chain inefficiencies that may drive ageing and disease. This targeted approach may explain why clinical studies have shown consistent benefits across different populations.
The evidence quality for SS-31 includes published data from clinical trials including the 12-participant TAZPOWER study. This provides genuine clinical evidence rather than just animal studies or anecdotal reports. Compare this to peptides like [Epithalon](/peptides/epithalon) or [MOTS-c](/peptides/mots-c), where human data remains limited.
For those considering SS-31, it's often compared to [PEG-MGF](/peptides/peg-mgf) and [IGF-1 LR3](/peptides/igf-1-lr3) for recovery applications, though SS-31's mitochondrial focus offers a different mechanistic approach. Some users combine it with [BPC-157](/peptides/bpc-157) for comprehensive recovery protocols.
Understanding proper dosing is crucial — clinical trials use 40mg daily, significantly higher than typical peptide doses. Proper preparation is essential for subcutaneous administration.
Mechanism of Action
SS-31 operates through a uniquely precise mechanism that appears to target mitochondrial dysfunction at its core. The peptide's structure — featuring alternating cationic and aromatic amino acids — allows it to penetrate cell membranes and concentrate in mitochondria at ratios exceeding 1000:1 compared to the surrounding cytoplasm.
Once inside mitochondria, research suggests SS-31 binds specifically to cardiolipin, a phospholipid that forms the architectural foundation of the inner mitochondrial membrane. Think of cardiolipin as the scaffolding that holds your cellular power plants together. When this scaffolding becomes damaged through oxidation — a natural consequence of energy production — mitochondrial efficiency plummets.
Studies indicate SS-31 stabilises this scaffolding, preventing cardiolipin peroxidation and maintaining proper cristae structure. This preservation appears critical because cristae house the respiratory complexes responsible for ATP synthesis. When cristae structure deteriorates, these complexes become inefficient, producing excess reactive oxygen species (ROS) while generating less energy.
The peptide's intervention is elegant: rather than scavenging ROS after they're produced (like traditional antioxidants), research suggests SS-31 prevents excessive ROS generation by optimising electron transport chain efficiency. It's the difference between mopping up spills and fixing the leaky pipe causing them — addressing the root cause rather than merely managing symptoms.
This mechanism specifically appears to enhance respiratory supercomplexes — particularly the interaction between Complex III and Complex IV. These supercomplex structures are essential for efficient electron transport, and their stabilisation may directly translate to improved ATP synthesis and reduced oxidative stress.
Research suggests SS-31 also helps prevent cytochrome c release and subsequent apoptosis, whilst enhancing mitochondrial membrane potential. Unlike [CJC-1295](/peptides/cjc-1295) or [Ipamorelin](/peptides/ipamorelin), which work through growth hormone pathways, SS-31's effects appear immediate and direct. The peptide may begin working within hours of administration, as evidenced by rapid improvements in cellular respiration measurements.
The mitochondrial concentration mechanism also may explain SS-31's broad therapeutic potential. Since mitochondrial dysfunction underlies numerous age-related diseases — from heart failure to neurodegenerative conditions — targeting this fundamental process could offer wide-ranging benefits. This contrasts with peptides like [Semaglutide](/peptides/semaglutide), which target specific receptor pathways for narrower therapeutic effects.